These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 16401712)

  • 1. Lung Cancer Highlights from ASCO 2005.
    Belvedere O; Grossi F
    Oncologist; 2006 Jan; 11(1):39-50. PubMed ID: 16401712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.
    Strauss GM; Herndon JE; Maddaus MA; Johnstone DW; Johnson EA; Harpole DH; Gillenwater HH; Watson DM; Sugarbaker DJ; Schilsky RL; Vokes EE; Green MR
    J Clin Oncol; 2008 Nov; 26(31):5043-51. PubMed ID: 18809614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.
    Cohen MH; Gootenberg J; Keegan P; Pazdur R
    Oncologist; 2007 Jun; 12(6):713-8. PubMed ID: 17602060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant Therapy of Resected Non-small Cell Lung Cancer: can We Move Forward?
    Buffoni L; Vavalà T; Novello S
    Curr Treat Options Oncol; 2016 Oct; 17(10):54. PubMed ID: 27523606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506).
    Zhou Q; Song Y; Zhang X; Chen GY; Zhong DS; Yu Z; Yu P; Zhang YP; Chen JH; Hu Y; Feng GS; Song X; Shi Q; Yang LL; Zhang PH; Wu YL
    BMC Cancer; 2017 Jul; 17(1):462. PubMed ID: 28673332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early-stage non-small-cell lung cancer: current perspectives in combined-modality therapy.
    Bunn PA
    Clin Lung Cancer; 2004 Sep; 6(2):85-98. PubMed ID: 15476594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high dose three-dimension conformal thoracic radiotherapy (74 Gy) with concurrent carboplatin, paclitaxel, and gefitinib in unresectable stage IIIA and stage IIIB non-small cell lung cancer.
    Stinchcombe TE; Morris DE; Lee CB; Moore DT; Hayes DN; Halle JS; Rivera MP; Rosenman JG; Socinski MA
    J Thorac Oncol; 2008 Mar; 3(3):250-7. PubMed ID: 18317067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II trial of preoperative concurrent radiation therapy and weekly paclitaxel/carboplatin for patients with locally advanced non-small-cell lung cancer.
    Hainsworth JD; Gray JR; Litchy S; Bearden JD; Shaffer DW; Houston GA; Greco FA
    Clin Lung Cancer; 2004 Jul; 6(1):33-42. PubMed ID: 15310415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of postoperative adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected stage II and IIIA non-small-cell lung cancer: promising long-term results of the Radiation Therapy Oncology Group--RTOG 9705.
    Bradley JD; Paulus R; Graham MV; Ettinger DS; Johnstone DW; Pilepich MV; Machtay M; Komaki R; Atkins J; Curran WJ;
    J Clin Oncol; 2005 May; 23(15):3480-7. PubMed ID: 15908657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Combined-modality therapy for lung cancer].
    Miura S; Yamamoto N
    Nihon Rinsho; 2010 Jun; 68(6):1121-8. PubMed ID: 20535966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality of life analyses from the randomized, open-label, phase III PointBreak study of pemetrexed-carboplatin-bevacizumab followed by maintenance pemetrexed-bevacizumab versus paclitaxel-carboplatin-bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.
    Spigel DR; Patel JD; Reynolds CH; Garon EB; Hermann RC; Govindan R; Olsen MR; Winfree KB; Chen J; Liu J; Guba SC; Socinski MA; Bonomi P
    J Thorac Oncol; 2015 Feb; 10(2):353-9. PubMed ID: 25611228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer.
    Reynolds C; Barrera D; Jotte R; Spira AI; Weissman C; Boehm KA; Pritchard S; Asmar L
    J Thorac Oncol; 2009 Dec; 4(12):1537-43. PubMed ID: 19887966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.
    Herbst RS; Giaccone G; Schiller JH; Natale RB; Miller V; Manegold C; Scagliotti G; Rosell R; Oliff I; Reeves JA; Wolf MK; Krebs AD; Averbuch SD; Ochs JS; Grous J; Fandi A; Johnson DH
    J Clin Oncol; 2004 Mar; 22(5):785-94. PubMed ID: 14990633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-line treatment for advanced non-small-cell lung cancer.
    Laskin JJ; Sandler AB
    Oncology (Williston Park); 2005 Nov; 19(13):1671-6; discussion 1678-80. PubMed ID: 16425521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pemetrexed-carboplatin adjuvant chemotherapy with or without gefitinib in resected stage IIIA-N2 non-small cell lung cancer harbouring EGFR mutations: a randomized, phase II study.
    Li N; Ou W; Ye X; Sun HB; Zhang L; Fang Q; Zhang SL; Wang BX; Wang SY
    Ann Surg Oncol; 2014 Jun; 21(6):2091-6. PubMed ID: 24585406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology.
    J Clin Oncol; 1997 Aug; 15(8):2996-3018. PubMed ID: 9256144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in our understanding of postoperative adjuvant chemotherapy in resectable non-small-cell lung cancer.
    Hotta K; Matsuo K; Kiura K; Ueoka H; Tanimoto M
    Curr Opin Oncol; 2006 Mar; 18(2):144-50. PubMed ID: 16462183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined modality therapy of non-small cell lung cancers.
    Juretic A; Sobat H; Samija M
    Ann Oncol; 1999; 10 Suppl 6():93-8. PubMed ID: 10676559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant Chemotherapy in Resected Stage II Non-small Cell Lung Cancer: Evaluating the Impact of Dose Intensity and Time to Treatment.
    Ramsden K; Laskin J; Ho C
    Clin Oncol (R Coll Radiol); 2015 Jul; 27(7):394-400. PubMed ID: 25800720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cisplatin/Pemetrexed Followed by Maintenance Pemetrexed Versus Carboplatin/Paclitaxel/Bevacizumab Followed by Maintenance Bevacizumab in Advanced Nonsquamous Lung Cancer: The GOIM (Gruppo Oncologico Italia Meridionale) ERACLE Phase III Randomized Trial.
    Galetta D; Cinieri S; Pisconti S; Gebbia V; Morabito A; Borsellino N; Maiello E; Febbraro A; Catino A; Rizzo P; Montrone M; Misino A; Logroscino A; Rizzi D; Di Maio M; Colucci G
    Clin Lung Cancer; 2015 Jul; 16(4):262-73. PubMed ID: 25582493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.